Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9889663 | 0.85 | CYP1A2 (0.40) | PLA2G2CCYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL508742 | 0.82 | ZDHHC20 (0.31) | CASRCYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL508173 | 0.82 | CYP1A2 (0.31) | CYP1A2CYP3A4CYP2C19KDM4EUSP2 | |
| SCHEMBL509068 | 0.82 | CYP1A2 (0.31) | CYP1A2CYP3A4CYP2C19KDM4EUSP2 | |
| SCHEMBL508829 | 0.79 | USP2 (0.31) | PLA2G2CCYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL16038177 | 0.78 | KDM4E (0.34) | CYP1A2CYP3A4CYP2C19KDM4EUSP2 | |
| SCHEMBL528216 | 0.76 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL509069 | 0.76 | — | — | |
| SCHEMBL18204281 | 0.73 | L3MBTL1 (0.33) | CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1562994 | 0.73 | HTT (0.53) | CYP1A2CYP3A4CYP2C19USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638614-B2 | Method for making silicone hydrogel contact lenses | ALCON INC. (CH) | 2026-05-26 | — | — | US | claimed |
| EP-4514596-B1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2026-03-04 | — | — | EP | claimed |
| US-20260042268-A1 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | ALCON INC (CH) | 2026-02-12 | — | — | US | claimed |
| US-20260042269-A1 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | ALCON INC (CH) | 2026-02-12 | — | — | US | claimed |
| EP-4657145-A2 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | Alcon Inc. (CH) | 2025-12-03 | — | — | EP | claimed |
| EP-4657144-A2 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | Alcon Inc. (CH) | 2025-12-03 | — | — | EP | claimed |
| US-20250223392-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC (CH) | 2025-07-10 | — | — | US | claimed |
| US-12286501-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | ALCON INC. (CH) | 2025-04-29 | — | — | US | claimed |
| EP-4514596-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2025-03-05 | — | — | EP | claimed |
| EP-4514597-A1 | METHOD FOR MAKING UV AND HEVL-ABSORBING OPHTHALMIC LENSES | Alcon Inc. (CH) | 2025-03-05 | — | — | EP | claimed |
| EP-1716436-B1 | (METH) ACRYLAMIDE MONOMERS CONTAINING HYDROXY AND SILICONE FUNCTIONALITIES AND POLYMERS MADE THEREFROM | JOHNSON & JOHNSON VISION CARE (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2010133680-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | NOVARTIS AG (CH) | 2010-11-25 | — | — | WO | claimed |
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | ALCON INC. (CH) | 2010-11-25 | — | — | US | claimed |
| US-20100258961-A1 | Method for making silicone hydrogel contact lenses | ALCON INC. (CH) | 2010-10-14 | — | — | US | claimed |
| WO-2010071691-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | NOVARTIS AG (CH) | 2010-06-24 | — | — | WO | claimed |
| US-20070167592-A1 | (METH)ACRYLAMIDE MONOMERS CONTAINING HYDROXY AND SILICONE FUNCTIONALITIES | JOHNSON & JOHNSON VISION CARE, INC. | 2007-07-19 | — | — | US | claimed |
| US-7214809-B2 | (Meth)acrylamide monomers containing hydroxy and silicone functionalities | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2007-05-08 | — | — | US | claimed |
| EP-1716436-A1 | (METH) ACRYLAMIDE MONOMERS CONTAINING HYDROXY AND SILICONE FUNCTIONALITIES AND POLYMERS MADE THEREFROM | Johnson and Johnson Vision Care, Inc. (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005078482-A1 | (METH)ACRYLAMIDE MONOMERS CONTAINING HYDROXY AND SILICONE FUNCTIONALITIES AND POLYMERS MADE THEREFROM | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2005-08-25 | — | — | WO | claimed |
| US-20050176911-A1 | (Meth)acrylamide monomers containing hydroxy and silicone functionalities | JOHNSON & JOHNSON VISION CARE, INC. | 2005-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042269-A1 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | CRYZ, STRA6, PHOSPHO1 | CASR 1300/4885PLA2G2C 45/4885CYP1A2 3826/4885 |
| US-20100296049-A1 | ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS | VCL, MACF1, CFL1 | CASR 2049/4885PLA2G2C 2594/4885CYP1A2 4509/4885 |
| US-20260042268-A1 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | STRA6, CRYZ, SMCHD1 | CASR 1810/4885PLA2G2C 813/4885CYP1A2 2887/4885 |
| US-12638614-B2 | Method for making silicone hydrogel contact lenses | SMCHD1, CRYAA, CRYZ | CASR 3290/4885PLA2G2C 3106/4885CYP1A2 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.